Heart transplantation: current status.
Two hundred ninety-three patients transplanted between March 1979 and October 1990 are reviewed. A comparison of survival curves suggests that our current triple therapy results in a half-life (15 years) which is twice that anticipated with either conventional or CsA and P therapy. Rejection occurs primarily in the first 1-3 months after transplantation and with our current therapy, is rarely seen thereafter. Infection, however, continues to be a threat with an incidence of approximately 10% per year. The major threats to long-term survival appear to be graft arteriosclerosis, infection, and malignancy.
Copeland
J G
JG
Department of Surgery, University of Arizona Health Sciences Center, Tucson.
Rosado
L J
LJ
Sethi
G
G
Huston
C
C
D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D016027:Heart Transplantation / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
D007166:Immunosuppressive Agents